Intelligence · Clinical Development
Pipeline search results
Programs matching “breast-cancer” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 272 pipeline programs matching "breast-cancer" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
docetaxel and ketoconazole
Hospital Authority, Hong Kong
Metastatic Breast Cancer
1 trial -
doxorubicin, docetaxel
Hospital Authority, Hong Kong
Metastatic Breast Cancer
1 trial -
entinostat
Syndax Pharmaceuticals
Estrogen Receptor-negative Breast Cancer
1 trial -
entinostat
Syndax Pharmaceuticals
Breast Cancer
4 trials -
hyperbaric oxygen
United Therapeutics Europe Ltd
Breast Cancer
1 trial -
nab-paclitaxel
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Breast Cancer
1 trial -
pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine
United Therapeutics Europe Ltd
Anatomic Stage I Breast Cancer AJCC v8
1 trial -
paclitaxel/carboplatin/lapatinib
Hospital Authority, Hong Kong
ErbB2-Positive Stage I-III Breast Cancer
1 trial -
pyrotinib and trastuzumab in combinition with neoadjuvant chemotherapy
The First People's Hospital of Lianyungang
HER2-positive Breast Cancer
1 trial -
surufatinib + fulvestrant + chidamide
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
ADCT-502
ADC Therapeutics SA
Breast Cancer
1 trial -
BCA-81472709
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Breast Cancer
1 trial -
BDC-3042
Bolt Biotherapeutics
Triple Negative Breast Cancer
1 trial -
BG-68501
BEONE MEDICINES AUS PTY LTD
Breast Cancer
1 trial -
BG-75202
BEONE MEDICINES AUS PTY LTD
Breast Cancer
1 trial -
BGB-21447
BEONE MEDICINES AUS PTY LTD
Hormone-receptor-positive Breast Cancer
1 trial -
BL-M07D1
Sichuan Baili Pharmaceutical Co.,
Breast Cancer
1 trial -
BioTTT001 injection
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Locally Advanced Breast Cancer (LABC)
1 trial -
CT-202
Context Therapeutics
Triple Negative Breast Cancer (TNBC)
1 trial -
Cemiplimab
Regeneron UK Limited
Hormone Receptor-positive Breast Cancer
1 trial -
Cyclophosphamide
United Therapeutics Europe Ltd
Breast Cancer
1 trial -
Dendritic Cell (DC1) Vaccine
VACCINEX, INC.
HER2-positive Breast Cancer
1 trial -
Dendritic Cell Vaccination
Quantum Biopharma
Metastatic Breast Cancer
1 trial -
ELVN-002
Enliven Therapeutics
HER2-positive Breast Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.